Comparative Pharmacology
Head-to-head clinical analysis: PROCANBID versus PROCAPAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCANBID versus PROCAPAN.
PROCANBID vs PROCAPAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; inhibits sodium channels, slowing conduction velocity, increasing effective refractory period, and suppressing automaticity.
Procapan is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, increasing their concentrations in the synaptic cleft.
Procainamide extended-release (Procanbid) is dosed based on ideal body weight. Typical adult dose: 500 mg to 1500 mg orally every 12 hours. Maximum dose: 3000 mg/day. Dose should be titrated to achieve therapeutic plasma procainamide and NAPA levels.
Adults: 10 mg orally three times daily; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-4.7 hours (procainamide) with normal renal function; clinical context: prolonged in renal impairment (up to 14 hours) and heart failure; NAPA half-life: 6-8 hours.
Terminal half-life: 6.5 hours (range 4-9 h) in normal renal function; prolonged in renal impairment (up to 15 h in ESRD)
Renal excretion: 50-60% unchanged; hepatic metabolism to N-acetylprocainamide (NAPA) with further renal elimination; total renal elimination of procainamide and NAPA >80%.
Renal: 70-80% unchanged; fecal: 10-20% as metabolites; biliary: <5%
Category C
Category C
Class Ia Antiarrhythmic
Class Ia Antiarrhythmic